Schaeffer's Top Stock Picks for '25

Pharma Stock Down Despite 'Clinically Meaningful' FDA Nod

Cantor Fitzgerald's $14 price target is double CYTK's current price

Digital Content Manager
Jan 22, 2019 at 10:44 AM
facebook X logo linkedin


The shares of Cytokinetics, Inc. (NASDAQ:CYTK) are down 1.3% at $6.76 in early trading, reversing pre-market gains, despite the Food and Drug Administration's (FDA) sign-off on the "Six Minute Walk Test" (6MWT) as the primary endpoint for a reldesemtiv registration program among patients with spinal muscular atrophy (SMA) who have maintained ambulatory function. The biotech company expects to begin additional studies of reldesemtiv in the first quarter.

Cantor Fitzgerald weighed in, calling the FDA nod "clinically meaningful," as "the 6MWT has been used for the FDA approval of a number of drugs." As such, the analyst maintains an "overweight" rating and $14 price target -- more than double CYTK's current price, and on pace with the consensus 12-month price target among Wall Street. Likewise, CYTK sports three "strong buy" opinions, compared to just one "hold."

CYTK stock gapped lower in November 2017, after the firm abandoned its treatment for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. The shares haven't recovered from that drop, with rebound attempts capped at the $10 area. More recently, the equity touched a three-year low of $5.90 on Dec. 27, and a subsequent bounce was halted at its 200-day moving average.

Short interest is down 9.8% in the past reporting period, but there's still plenty of pessimism surrounding CYTK stock. Currently, the 2.6 million shares sold short represent 5% of the stock's available float. It would take almost two weeks for traders to buy back their bearish bets, at the equity's average daily trading volume. However, these skeptics have little reason to abandon ship yet, considering the stock's struggles on the charts of late.

In the options pits, CYTK's Schaeffer's put/call open interest ratio (SOIR) of 1.17 sits in the 85th percentile of its annual range, suggesting that short-term options players are more put-heavy than usual right now. Most popular is the in-the-money February 10 put, with just over 600 contracts outstanding.

 
 

You have the chance to join one of Bernie's most exclusive programs, complete access at HUGE savings!

As we prepare for a new administration to take the reins in Washington, the near-term market landscape is rife with uncertainty.

The Federal Reserve has already hinted at the turbulence ahead, lowering its interest rate outlook for 2025.

Meanwhile, breakthroughs in artificial intelligence (AI), quantum computing, and other transformative sectors have unlocked incredible profit potential.

But these opportunities are fleeting, and timing is everything. That's where Quick-Hit Trader comes in.

Quick-Hit Trader is designed for precision and speed, getting you in and out of the market in a flash. While other investors scramble to navigate volatile conditions, you'll have access to expertly curated trades that leverage these rapid shifts to deliver explosive profits in short order.

This is your chance to capitalize on the fast-moving market like never before. Are you ready to make your move?

 

 

(function(doc, script) { var js, fjs = doc.getElementsByTagName(script)[0], frag = doc.createDocumentFragment(), add = function(url, id) { if (doc.getElementById(id)) {return;} js = doc.createElement(script); js.src = url; id && (js.id = id); frag.appendChild( js ); }; // Google+ button //add('https://apis.google.com/js/platform.js', async="defer"); // Facebook SDK add('//connect.facebook.net/en_US/all.js#xfbml=1&appId=772755279557744', 'facebook-jssdk'); // Twitter SDK //add('//platform.twitter.com/widgets.js', charset='utf-8'); fjs.parentNode.insertBefore(frag, fjs); }(document, 'script'));